Importantly, we provide evidence that measuring the levels of sXBP1 transcripts in tumors by using a fully automatable genetic method based on fragment analysis is clinically relevant, this especially as the expression of sXBP1 is not easily captured by classical transcriptomic platforms for technical reasons (except maybe in public RNAseq datasets using high read depths), and, therefore, the clinical relevance of XBP1 splicing in cancer development and progression has not been specifically addressed. This evidence concerns the gene XBP1 and cancer.